| dbo:abstract |
ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients. ARIAD’s most prominent drug discoveries include Iclusig, designed for patients with all forms of Philadelphia chromosome-positive [Ph+] chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to or unable to tolerate other tyrosine kinase inhibitors, and brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016 and was approved in the U.S. in April 2017. In January 2017, Takeda announced it would acquire ARIAD for $5.2 billion, expanding the company's oncology and hematology business. On February 16, 2017, Takeda Pharmaceuticals, Ltd. announced it had completed its acquisition of ARIAD and incorporated ARIAD into Takeda Oncology. (en) |
| dbo:assets |
5.4669E8 |
| dbo:fate |
Merged withTakeda Pharmaceuticals (en) |
| dbo:foundingYear |
1991-01-01 (xsd:gYear) |
| dbo:industry |
dbr:Pharmaceutical_company dbr:Biotechnology |
| dbo:keyPerson |
dbr:Harvey_Berger |
| dbo:location |
dbr:Cambridge,_Massachusetts dbr:United_States |
| dbo:numberOfEmployees |
380 (xsd:nonNegativeInteger) |
| dbo:product |
dbr:Brigatinib dbr:Ridaforolimus dbr:Ponatinib |
| dbo:revenue |
1.188E8 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/ARIAD_logo.png?width=300 |
| dbo:type |
dbr:Public_company |
| dbo:wikiPageExternalLink |
http://medinol.com/ http://www.ariad.com/ https://www.takeda.com/ |
| dbo:wikiPageID |
20737471 (xsd:integer) |
| dbo:wikiPageLength |
16193 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1041883146 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Cambridge,_Massachusetts dbr:Blood_clot dbr:Brigatinib dbr:Pfizer dbr:Pharmaceutical_company dbr:Ridaforolimus dbr:United_States dbr:United_States_Dollar dbr:Public_company dbc:1991_establishments_in_Massachusetts dbc:Biotechnology_companies_of_the_United_States dbr:Anaplastic_lymphoma_kinase dbr:Massachusetts dbr:Chronic_myelogenous_leukemia dbr:Lung_cancer dbr:PDL_BioPharma dbr:Bristol-Myers_Squibb dbc:Companies_based_in_Cambridge,_Massachusetts dbr:Acute_lymphoblastic_leukemia dbc:2017_mergers_and_acquisitions dbr:Food_and_Drug_Administration dbr:Deloitte_Fast_500 dbr:KIT_(gene) dbr:RET_proto-oncogene dbc:Companies_formerly_listed_on_the_Nasdaq dbr:Harvey_Berger dbc:Biotechnology_companies_established_in_1991 dbc:Defunct_pharmaceutical_companies_of_the_United_States dbc:Life_sciences_industry dbc:Merck_&_Co. dbc:Pharmaceutical_companies_disestablished_in_2017 dbc:Pharmaceutical_companies_established_in_1991 dbc:Takeda_Pharmaceutical_Company dbr:Lausanne dbr:Biotechnology dbr:Takeda_Pharmaceutical_Company dbr:Philadelphia dbr:Ponatinib dbr:Royalty_financing dbr:FGFR1 dbr:FGFR2 dbr:FGFR3 dbr:FGFR4 dbr:Merck_&_Co. dbr:Oncology dbr:Tyrosine_kinase dbr:Takeda_Pharmaceuticals dbr:MTOR_inhibitor |
| dbp:assets |
5.4669E8 |
| dbp:fate |
Merged with Takeda Pharmaceuticals (en) |
| dbp:foundation |
1991 (xsd:integer) |
| dbp:homepage |
http://www.ariad.com/ |
| dbp:industry |
dbr:Pharmaceutical_company dbr:Biotechnology |
| dbp:keyPeople |
Chairman of the Board (en) President of Research and Development and Chief Scientific Officer (en) Alex Denner, (en) Ed Fitzgerald, (en) Founder, chairman, and CEO Emeritus (en) Harvey Berger, (en) Marty Duvall, (en) Timothy P. Clackson, (en) |
| dbp:location |
dbr:Cambridge,_Massachusetts dbr:United_States |
| dbp:logo |
ARIAD logo.png (en) |
| dbp:logoSize |
151 (xsd:integer) |
| dbp:name |
ARIAD Pharmaceuticals, Inc. (en) |
| dbp:netIncome |
US$ million (en) |
| dbp:numEmployees |
380 (xsd:integer) |
| dbp:operatingIncome |
US$ million (en) |
| dbp:products |
dbr:Brigatinib dbr:Ridaforolimus dbr:Ponatinib AP32788 (en) Rimiducid (en) |
| dbp:revenue |
1.188E8 |
| dbp:tradedAs |
NASDAQ:ARIA (en) |
| dbp:type |
dbr:Public_company |
| dbp:wikiPageUsesTemplate |
dbt:Authority_control dbt:Color dbt:Decrease dbt:End_date_and_age dbt:Infobox_company dbt:Portal dbt:Reflist dbt:Short_description dbt:IncreaseNegative dbt:Pharmaceutical_companies_of_the_United_States |
| dcterms:subject |
dbc:1991_establishments_in_Massachusetts dbc:Biotechnology_companies_of_the_United_States dbc:Companies_based_in_Cambridge,_Massachusetts dbc:2017_mergers_and_acquisitions dbc:Companies_formerly_listed_on_the_Nasdaq dbc:Biotechnology_companies_established_in_1991 dbc:Defunct_pharmaceutical_companies_of_the_United_States dbc:Life_sciences_industry dbc:Merck_&_Co. dbc:Pharmaceutical_companies_disestablished_in_2017 dbc:Pharmaceutical_companies_established_in_1991 dbc:Takeda_Pharmaceutical_Company |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 yago:WikicatBiotechnologyCompaniesOfTheUnitedStates yago:WikicatCompaniesBasedInCambridge,Massachusetts yago:WikicatCompaniesEstablishedIn1991 yago:WikicatCompaniesInTheNASDAQBiotechnologyIndex yago:WikicatCompaniesListedOnNASDAQ yago:Abstraction100002137 yago:Company108058098 yago:DrugCompany108002578 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity dbo:Organisation yago:SocialGroup107950920 yago:WikicatPharmaceuticalCompaniesOfTheUnitedStates |
| rdfs:comment |
ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients. In January 2017, Takeda announced it would acquire ARIAD for $5.2 billion, expanding the company's oncology and hematology business. On February 16, 2017, Takeda Pharmaceuticals, Ltd. announced it had completed its acquisition of ARIAD and incorporated ARIAD into Takeda Oncology. (en) |
| rdfs:label |
ARIAD Pharmaceuticals (en) |
| owl:sameAs |
freebase:ARIAD Pharmaceuticals yago-res:ARIAD Pharmaceuticals wikidata:ARIAD Pharmaceuticals https://global.dbpedia.org/id/4KMhZ |
| skos:closeMatch |
http://www.grid.ac/institutes/grid.418092.6 http://www.grid.ac/institutes/grid.476109.d |
| prov:wasDerivedFrom |
wikipedia-en:ARIAD_Pharmaceuticals?oldid=1041883146&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/ARIAD_logo.png |
| foaf:homepage |
http://www.ariad.com/ |
| foaf:isPrimaryTopicOf |
wikipedia-en:ARIAD_Pharmaceuticals |
| foaf:name |
ARIAD Pharmaceuticals, Inc. (en) |
| is dbo:institution of |
dbr:Joan_Brugge |
| is dbo:wikiPageRedirects of |
dbr:Ariad_Pharmaceuticals dbr:ARIAD_Pharmaceuticals,_Inc. |
| is dbo:wikiPageWikiLink of |
dbr:Bcr-Abl_tyrosine-kinase_inhibitor dbr:Apricus_Biosciences dbr:Ridaforolimus dbr:David_Blech dbr:List_of_pharmaceutical_companies dbr:Targeted_molecular_therapy_for_neuroblastoma dbr:Ariad_Pharmaceuticals,_Inc._v._Eli_Lilly_&_Co. dbr:Stuart_Schreiber dbr:Protein_kinase_inhibitor dbr:Joan_Brugge dbr:Haggar_Hilda_Ampadu dbr:Harvey_Berger dbr:Ponatinib dbr:I._Elaine_Allen dbr:Ariad_Pharmaceuticals dbr:ARIAD_Pharmaceuticals,_Inc. |
| is foaf:primaryTopic of |
wikipedia-en:ARIAD_Pharmaceuticals |
